Sagent Pharma plans $100M IPO for generic injectables

Sagent Pharma plans $100M IPO. Sagent Holding Co., the Schaumburg, Illinois, company that is developing generic injectable pharmaceuticals, has filed for a $100 million initial public offering just as a host of drug companies tap public capital markets, with many seeking to raise proceeds for research, according to the Wall Street Journal.

Health IT attracts private equity. Healthcare insiders — especially savvy venture capitalists — know there’s more true reform in the $27 billion electronic medical record subsidy program than in the so-called “healthcare reform” legislation passed this year that mostly throws more money down the same volume-based fee-for-service rat hole, according to FierceHealthIT.

*****

Update: 11 July 2016 / Schaumburg, Illinois-based Sagent Pharmaceuticals has agreed to be acquired by Nichi-Iko Pharmaceutical of Tokyo for about $736 million.